Capital Building in Washington DC

Advocacy & Policy

To improve patient care, ASCO advocates for increased federal funding for research, greater health care access, value in cancer care, and payment reform.

  • 2020 Fee Schedule Proposal Outlines E&M Code Changes, MIPS Changes

    CMS is proposing to align Evaluation & Management (E&M) coding with changes laid out by the Current Procedural Terminology Editorial Panel for office/outpatient E&M visits, along with proposed changes to the Quality Payment Program.

    Read More
  • Drug Pricing Bill Should Protect Patients, Encourage Interoperability

    ASCO submitted comments to a Senate Finance Committee markup on the “The Prescription Drug Pricing Reduction Act (PDPRA),” a package of proposals aimed at addressing the high cost of prescription drugs.

    Learn More
  • Proposed Opioid Blister Packaging Requirements and Cancer-Related Pain

    In a comment letter to the acting FDA commissioner, ASCO expressed concerns that a proposed modification to the existing Opioid Analgesic Risk Evaluation and Mitigation Strategy (OA REMS) could adversely affect patients with cancer-related pain.

    Read More

Random Quote

"Precision medicine has begun to transform the lives of many patients with cancer, but its application in clinical practice is enormously complex. ASCO hopes to contribute to and advance the field by providing oncologists with the training, tools, and data they need."
Richard L. Schilsky, MD, FACP, FASCO
ASCO Chief Medical Officer